LONDON, UNITED KINGDOM--(Marketwired - Apr 3, 2014) - Visionary medical device company ZELTIQ Aesthetics, Inc. (
As the latest addition to the successful CoolSculpting® range of applicators, CoolSmooth, when combined with CoolFit™ designed to treat the inner thigh, now provides patients with the opportunity to treat the entire thigh area.
A recent CoolSmooth clinical study of female patients who received unilateral outer thigh treatments reflected high levels of patient satisfaction:
- 86% of patients noticed visible fat reduction after just one treatment
- 86% of patients were satisfied with their results
- 89% of patients would recommend the CoolSculpting procedure to a friend1
"The introduction of the CoolSmooth applicator provides a new solution to individuals who struggle to reduce fat in the thigh area, a difficult-to-treat part of the body," said Mark Foley, President and Chief Executive Officer of ZELTIQ. "Through our newest applicator, we are excited by the opportunity to expand our current offerings to physicians and, ultimately, the individuals who may benefit from our unique technology. Results achieved with CoolSmooth add to the growing body of evidence demonstrating the safety, efficacy and long-lasting results of the CoolSculpting procedure."
"The CoolSculpting system offers excellent results for patients who find it difficult to eliminate fat on certain parts of their bodies," said Dr. Natalie Blakely, Cosmetic Doctor and founder of the Light Touch clinic. "The introduction of the CoolSmooth applicator, now extends the areas available for treatment from the CoolSculpting range, which include three particularly challenging parts of the body -- the abdomen, flank and now thighs - and will be welcomed by those who wish to improve the contour of their bodies without invasive surgery."
A recent market research study revealed that 7.2 million people expressed an interest in CoolSculpting as a solution for inner or outer thigh fat1. This is in addition to the 13.2 million and 7.4 million interested in undergoing the CoolSculpting treatment for the abdomen and flank1, respectively.
In the UK, the CoolSculpting treatment is approved for general non-invasive fat reduction. Each CoolSculpting treatment results in a noticeable reduction of fat in the treated areas, and the treated fat cells are gone for good. Most patients can start to see results as soon as three weeks following treatment, with the most dramatic results occurring over a period of one to three months. Every patient is unique, which is why ZELTIQ recommends a customized treatment plan as part of the initial consultation. Additional treatments in the same or multiple areas may enhance the desired aesthetic effect.
Notes to Editors
About the CoolSculpting®Procedure
The CoolSculpting procedure is a non-surgical, clinically proven procedure that selectively reduces fat bulges in problem areas using a patented cooling technology. The CoolSculpting procedure is U.S. FDA-cleared and CE marked as a Class IIa medical device. It gently cools unwanted fat cells in the body to induce a natural, controlled elimination of fat cell without harming surrounding tissue, and the treated fat cells are gone for good. Over 1,000,000 CoolSculpting cycles and 2,200 systems have been shipped to more than 60 countries. The CoolSculpting procedure is available through an elite network of CoolSculpting centers worldwide. Dermatologists, plastic surgeons and leading aesthetic specialists that offer CoolSculpting can be found at www.coolsculpting.co.uk.
About ZELTIQ® Aesthetics, Inc.
ZELTIQ Aesthetics, Inc. is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat that may not respond to diet or exercise. The CoolSculpting procedure is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed the CoolSculpting procedure to safely, noticeably, and measurably reduce the fat layer.
References: 1. Data on file. ZELTIQ Aesthetics, Inc.
- Health Care Industry